Abstract
TET2/ASXL1 CHIP mutations with VAF > 2% combined with high inflammatory status were indicative of high mortality in patients with STEMI. Additionally, TET2/ASXL1 mutation with a VAF > 0.5% favored the recognition of vulnerable plaque features in patients with STEMI.
Introduction
As we age, blood stem cells can acquire somatic mutations leading to the proliferation of mutated white blood cells, a condition known as Clonal Hematopoiesis of Indeterminate Potential (CHIP). While not a malignancy, CHIP is an independent risk factor for cardiovascular disease. Historically, CHIP has been defined by a Variant Allele Frequency (VAF) of >2%. However, the clinical impact of "low-frequency" variants (VAF 0.5%–2%) in acute myocardial infarction (AMI) patients remains poorly understood.
This study investigates how CHIP mutations—specifically in genes like TET2 and ASXL1—affect long-term prognosis and the physical characteristics of arterial plaques in patients with ST-elevation myocardial infarction (STEMI). By evaluating mutations across various VAF thresholds, the researchers provide in vivo evidence linking these genetic variants to high-risk plaque morphologies and increased mortality.
Methods
The researchers employed targeted deep sequencing with Unique Molecular Identifiers (UMIs) on genomic DNA from peripheral blood mononuclear cells (PBMCs) to detect CHIP mutations down to a 0.5% VAF threshold. To assess the physical characteristics of the culprit arterial lesions, high-resolution Optical Coherence Tomography (OCT) was performed during percutaneous coronary intervention (PCI). Plaque morphology was classified based on markers of vulnerability, including Ruptured Fibrous Caps (RFC), Intact Fibrous Caps (IFC), Thin-Cap Fibroatheromas (TCFA), and macrophage infiltration. Statistical analyses, including Kaplan-Meier curves and Cox proportional hazards regressions, were used to evaluate Major Adverse Cardiovascular Events (MACE) and all-cause mortality over a 4-year follow-up period.
Datasets and Study Design
The study analyzed a prospective cohort of 1,403 STEMI patients treated at Fuwai Hospital in Beijing, China. A subset of 355 patients with de novo culprit lesions underwent detailed plaque morphology analysis via OCT.
Key Results
Prevalence of CHIP Mutations
The prevalence of CHIP mutations increased significantly as the detection threshold was lowered. At the standard >2% VAF, prevalence was 11.2%, but this rose to 45.2% when the threshold was lowered to >0.5% VAF.
Impact on Mortality and Inflammation
The study identified a critical synergy between CHIP mutations and systemic inflammation. Patients carrying TET2 or ASXL1 mutations had significantly higher mortality rates (e.g., 17.1% vs. 10.1% for VAF > 2%). This risk was most pronounced in patients with high systemic inflammation (hsCRP > 5.8 mg/L); those with both a TET2/ASXL1 mutation and high inflammation faced a 38.7% mortality rate, compared to 5.8% for those with neither.
Plaque Vulnerability
Low-frequency mutations proved clinically relevant for identifying dangerous plaque phenotypes. Patients with TET2/ASXL1 mutations (VAF > 0.5%) showed a higher prevalence of ruptured fibrous caps (70.2% vs. 47.1%) and thin-cap fibroatheromas (74.9% vs. 51.9%), providing a mechanistic link between these mutations and acute cardiac events.
Therapeutic Implications
Interestingly, CHIP carriers appeared to derive greater prognostic benefit from intensive statin therapy than non-carriers. Carriers at the >2% VAF threshold showed a dramatic reduction in mortality risk when discharged on statins (Hazard Ratio 0.07), suggesting that CHIP status could serve as a biomarker for precision cardiology.
Discussion and Limitations
While this study provides compelling in vivo evidence, it is limited by its single-center design and the fact that OCT imaging was available for only a portion of the cohort. The observed treatment interactions are based on observational data and require validation through randomized controlled trials (RCTs). Future research should focus on multicenter studies and RCTs to confirm whether anti-inflammatory or lipid-lowering therapies should be specifically tailored for CHIP-positive heart attack survivors.
Summary updated